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Letters to the Editor
Impact of Stent Fractures
Following Femoropopliteal Stenting
With great interest we read the prospective registry of stent
fractures after femoropopliteal stenting in a recent issue of the
Journal (1). The observed rate of fractures of nitinol stents, which
represent an essential progress compared with the use of balloon-
expandable stents or wall stents, is astonishingly high in contrast to
other studies and our own experience. We therefore regard it as
essential to make some critical comments to avoid a too high
assessment of the single-center observation.
The described results touch on an observational series in a single
center, laid out prospectively and described as a register. However,
a registry demands an external monitoring and evaluation of the
results. This did not happen. Three types of stents, in varying
numbers and of different lengths, were inserted into the vessels.
In 93 patients, 121 extremities were treated interventionally;
261 stents were implanted. Moreover, the mean length of the
stented segments was different in all, with the highest in the
Luminexx stent with 168 mm (SD 94 mm). This is remarkably
high, because, with a maximum stent length of 120 mm, more than
two stents had to be used in various patients. But this is explicitly
mentioned under precautions in the instructions for use.
Furthermore, in the publicized pictures of stent fractures of the
original study and at different presentations at international con-
gresses, only Luminexx stents are exposed. This is probably
explained by the fact that a Luminexx stent, in comparison to a
SMART or SelfX stent, is much more visible under X-ray.
However, this can lead to a wrong assessment and overestimation
of stent fractures. Furthermore, the color-coded duplex sonogra-
phy was only used for stent patency. Therefore, the visual assess-
ment of the stent has to be checked externally or carried out
independently.
Finally, in different illustrations, stent implantations were
shown without overlapping and also in the distal third of the
superficial femoral artery (SFA) and in the first and second
segment of the popliteal artery. In turn, this is obviously listed as
a contraindication in the instructions for use. Therefore, the
progress of the usage of nitinol stents in the SFA should not be
questioned by an observational series done at a single center.
Preferably, one should await the results of scientifically relevant
prospective controlled and randomized studies.
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Bridging the Resource Gap in Heart
Failure Expertise and Management: The
Underacknowledged Role of Nurse Specialists
Recent studies in the Journal have raised concerns regarding the
limited availability of heart failure (HF) specialists. Because HF
care now incorporates increasingly complicated strategies and
technologies, and because the number of HF patients is burgeon-
ing, capable and specialized providers are in greater demand. The
backbone of management must not be forgotten, however, and, as
Konstam (1) suggests, “highly specialized clinicians” will clearly be
needed to master the evaluation of the HF patient and the timing
of HF interventions. The foundation of HF care rests upon the
cognitive aspects: identifying and diagnosing the problem, using
evidence-based medications, maintaining appropriate intravascular
volume status, educating patients about the disease process, and
considering device-related and end-of-life issues. Those termed
“plumbers” and “electricians” by Naccarelli (2) should not replace,
but augment, those who provide the cognitive aspects of HF care.
However, economic remuneration and exciting advances in
procedural therapies have led many cardiologists away from the
core of HF management, resulting in a shortage of HF providers.
Less attention has been paid to the comprehensive strategies
provided by specially trained nurses who have shown improved HF
outcomes in the past and should not be overlooked as other
solutions are posed. When studied in the context of multidisci-
plinary teams, often led by cardiologists, nurse specialists have been
shown to contribute significantly to improving outcomes. The
review by McAlister et al. (3) of 29 trials has identified that one of
the three “crucial” elements in a successful program is the use of
specially trained HF nurses. What role do nurse specialists have in
HF management? They are able to monitor patients’ intravascular
volume status, titrate HF medications, triage and often avert
admissions with appropriate telemanagement, and educate patients
and families. Additionally, nurse specialists assist with complex
levels of care when faced with end-stage strategies of transplant,
end-of-life issues, or mechanical support.
Finally, the growing global burden of HF necessitates the
investigation into alternative methods of providing coordinated,
integrated, and focused care for patients. Though a clear need
exists for subspecialized care of HF patients so that all appropriate
options can be provided, the role that nurse specialists play in
managing patients across the spectrum should be fully acknowl-
edged. Nurse specialists should be part of the solution to the
growing HF provider shortage, as multidisciplinary HF team
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members, in a position that enhances and complements the vital
role of “cognitive, electrician, or plumber” HF cardiologists.
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Echocardiographic Findings in
Patients With Arrhythmogenic Right
Ventricular Cardiomyopathy/Dysplasia
We read with interest the study by Yoerger et al. (1) presenting
echocardiographic data of 29 probands affected by arrhythmogenic
right ventricular cardiomyopathy (ARVC) diagnosed with the
International Society and Federation of Cardiology task force
criteria. In all cases the echocardiogram showed typical features of
the disease. It is well known that ARVC diagnosis is made
considering different parameters. The purpose of their study was to
assess echocardiographic abnormalities in a series of patients
affected by ARVC, in whom the echocardiogram has not been
considered for the diagnosis.
Thus, we can assume that all these patients showed a clear form
of the disease, fulfilling the diagnostic criteria even in the absence
of the echocardiographic tool. However, the real problem is to
understand whether the typical ARVC echocardiographic alter-
ations have a diagnostic value per se, even when the task force
criteria (2 major, 1 major plus 2 minor, 4 minor) are not satisfied.
This point is critical because in the presymptomatic phase of the
disease the lack of diagnosis can lead to heavy consequences for the
subjects, who could be at risk of life-threatening ventricular
arrhythmias and sudden death.
Moreover, genetic studies (2) demonstrated that mutation
carriers often do not fulfill the published criteria. This leads to the
need to reevaluate the present task force criteria and to reexamine
the different echocardiographic abnormalities, trying to assess
which of these are specific to make a diagnosis of ARVC in the
absence of other codified criteria.
As shown by the investigators, a correct echocardiographic
evaluation can lead to the detection of several morphologic and
kinetic aspects of the right ventricle. At this point, considering that
an echocardiogram is a noninvasive technique that can be repeated
in time, can we consider this diagnostic tool as the “gold standard”
of ARVC diagnosis in asymptomatic patients or in patients with
minor forms of the disease (3)? Hence, the real significance of
echocardiographic abnormalities in this group of “uncertain sub-
jects” constitutes the major challenge in echocardiographic evalu-
tion of ARVC.
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REPLY
Dr. Bauce and colleagues raise several issues with regard to our
investigation of the echocardiographic findings in arrhythmogenic
right ventricular dysplasia (ARVD). The first is to indicate that our
patients all met the task force criteria for ARVD/C without the
echocardiographic-derived data. Therefore, the diagnosis was ob-
vious without the data. This was an intrinsic design of our study
(1), as one cannot assess the utility of a diagnostic method without
having a firm diagnosis of the disease excluding the test that is
being evaluated because there is no “gold standard.”
The purpose of our report was to identify the best quantitative
echocardiographic markers of ARVD in individuals meeting task
force criteria for ARVD (2). The data presented compare the
measurements of different right ventricular (RV) dimensions in
ARVD probands versus controls. We found that the right ventricular
outflow tract was the most commonly enlarged dimension in ARVD
probands. We provided a numerical value that separated the two
groups. At present, it is not uncommon for echocardiographic
laboratories to report only qualitative RV size. In order to discriminate
the normal RV from the abnormal, as is required in the assessment for
ARVD, quantitative measurements should be used.
Additionally, Dr. Bauce and colleagues correctly point out the
difficulty detecting ARVD in its preclinical or “presymptomatic”
phase. We agree that there is an important need to be able to
detect minimal structural abnormalities of the RV in patients
suspected of ARVD. Upon its completion, the Multidisciplinary
Registry of ARVD will have quantitative data from echocardio-
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